Physician profile
John D Nangle
NPI 1881860963
$2,788.84
in general payments reported to CMS, 2019-2025
44 companies · $40.95 in 2025
The $40.95 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,106 · 2022: $428 · 2023: $180 · 2024: $33.38 · 2025: $40.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $254.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $438.01 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $281.80 | 2021 | |
| Biogen, INC. | $164.56 | 2021 | |
| Novo Nordisk INC | $161.86 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $160.26 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $137.52 | 2021 | |
| Mallinckrodt Hospital Products INC. | $121.34 | 2021 | |
| Amgen INC. | $114.15 | 2021 | |
| Sunovion Pharmaceuticals INC. | $77.87 | 2021 | |
| Novartis Pharmaceuticals Corporation | $77.24 | 2021 | |
| Octapharma USA, INC. | $73.55 | 2021-2022 | |
| Pfizer INC. | $71.83 | 2021-2023 | |
| Genzyme Corporation | $68.41 | 2021 | |
| Neurelis, INC. | $62.66 | 2021 | |
| Ucb, INC. | $56.84 | 2021 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Nangle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.